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A B S T R A C T
Mycoplasma hyopneumoniae is the etiologic agent of porcine enzootic pneumonia, a contagious respiratory dis-
ease, causing significant economic losses worldwide. Antibiotic treatment is commonly utilised in the pig in-
dustry to control M. hyopneumoniae infection. Since the conventional antibiotic susceptibility test is time-con-
suming, taking up to weeks’ period, antibiotics are usually empirically chosen.
Certain single nucleotide polymorphisms in the parC (C239A/T, G250A) and gyrA (G242C, C247 T, A260 G)
genes show correlation with decreased fluoroquinolone susceptibility by the change of the target site.
Furthermore, the nucleotide alteration A2059 G in the 23S rRNA sequence correlates with significantly de-
creased macrolide and lincosamide susceptibility of M. hyopneumoniae. Mismatch amplification mutation assays
(MAMA) and high resolution melt (HRM) analysis, capable to detect the mentioned resistance markers, were
developed in the present study, in order to provide susceptibility data in a considerably shorter time than the
conventional methods. The results of the MAMA and HRM assays were congruent with the results of the con-
ventional antibiotic susceptibility method of the tested M. hyopneumoniae field isolates. The sensitivity of the
MAMAs was 103-104 copy numbers, while that of the HRM assay was 105-106 copy numbers.
To the best of our knowledge this was the first time that MAMA and HRM assays were developed for the rapid
detection of decreased fluoroquinolone, macrolide or lincosamide susceptibility in M. hyopneumoniae strains.
1. Introduction
Mycoplasma hyopneumoniae is the causative agent of enzootic
pneumonia, a contagious respiratory disease causing significant eco-
nomic losses worldwide (Silva et al., 2019). Beside vaccination, which
is not capable to completely prevent colonisation of the respiratory
tract (Thacker et al., 1998; Maes et al., 2017), antibiotic treatment is
frequently used in the disease control. Several antibiotics (e.g. pleur-
omutilines or tetracyclines) are effective against M. hyopneumoniae
(Maes et al., 2008, 2017), however mycoplasmas are naturally resistant
against certain agents (e.g. ß-lactams, glycopeptides) (Gautier-
Bouchardon, 2018). Since isolation and in vitro antibiotic susceptibility
testing of M. hyopneumoniae is time-consuming and fastidious, the an-
tibiotics are rather empirically chosen. However, the inappropriate use
of the agents may contribute to the emergence of resistance nor is it
cost-effective. Acquired resistance of M. hyopneumoniae was observed
against fluoroquinolones, macrolides and lincosamides in the past
decades (Stakenborg et al., 2005; Le Carrou et al., 2006; Vicca et al.,
2007; Gautier-Bouchardon, 2018).
Single nucleotide polymorphisms (SNPs) can cause conformation
changes of the target regions of certain antibiotics, leading to resistance
against the agent (Pirmohamed and Park, 2001). SNPs resulting in
amino acid alterations in the parC and gyrA genes show correlation with
decreased fluoroquinolone susceptibility of M. hyopneumoniae (Felde
et al., 2018). Furthermore, substitutions in the 23S rRNA sequence play
an important role in decreased susceptibility to macrolides and linco-
samides in mycoplasmas (Stakenborg et al., 2005; Felde et al., 2018).
Molecular biological methods like mismatch amplification mutation
assay (MAMA) or high resolution melt (HRM) analysis are able to detect
the SNPs correlating with the decreased antibiotic susceptibility
(Sulyok et al., 2018). The aim of the study was to design molecular
biological assays for the rapid detection of nucleotide substitutions
showing relation with decreased antibiotic susceptibility in M. hyop-
neumoniae.
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2. Materials and methods
2.1. Samples
Porcine lung samples with typical mycoplasmal lesions were col-
lected from Hungarian slaughterhouses with the permission of the
owners. Friis broth medium was used for the isolation of M. hyopneu-
moniae (Friis, 1975) as previously described (Felde et al., 2018). DNA
extraction was performed from stationary phase broth media with a
maximum of three passages, using the QIAamp DNA mini kit (Qiagen
Inc., Hilden, Germany) according to the manufacturer’s instructions.
The DNA samples were used as templates for all assays described in the
study.
Antibiotic susceptibility profiles of 44 Hungarian M. hyopneumoniae
isolates and the type strain (NCTC 10,110) were defined previously by
microbroth dilution method according to Hannan (2000), and de-
creased susceptibility to fluoroquinolones, macrolides and lincosamides
was detected in certain strains (Felde et al., 2018). Since there is no
official breakpoint for the antibiotic susceptibility testing of M. hyop-
neumoniae, MIC values suggested in previous publications were used to
categorize the susceptibility of the strains (Felde et al., 2018). There-
fore, strains, which were inhibited by ≥2 μg/ml MIC values of fluor-
oquinolones and/or ≥4 μg/ml MIC values of macrolides, were con-
sidered resistant, while strains inhibited by lower MIC values were
considered susceptible according to Hannan et al. (1997). Both initial
MIC values (defined when the growth control changed colour) and final
MIC values (defined in the absence of further colour change) were re-
corded. The type strain with low minimum inhibitory concentration
(MIC) values and field isolates with significantly increased MIC values
of fluoroquinolones (MycSu1; 15; 18; 20; 39; 50), macrolides and lin-
cosamides (MycSu18) were involved in the development of the mole-
cular assays. The initial and final MIC values of fluoroquinolones,
macrolides and lincosamides are summarised in Supplementary
Table 1.
2.2. MAMA and HRM design
Previously determined genetic markers, correlating with decreased
fluoroquinolone (C239 T/A and G250A in the parC gene; G242C, C247
T and A260 G in the gyrA gene, according to numbering of Escherichia
coli strain K-12 substrain MG1655, GenBank accession number
CP014225), macrolide and lincosamide (A2059 G in the 23S rRNA;
Supplementary Table 1) susceptibility in M. hyopneumoniae (Felde
et al., 2018) were targeted by mismatch amplification mutation assay
(MAMA) and high resolution melt (HRM) assay.
In the present study, MAMAs were designed and tested for the de-
tection of SNPs related to fluoroquinolone, macrolide and lincosamide
resistance using competing primers (Birdsell et al., 2012; Sulyok et al.,
2018). The assays were designed to show more than 2 °C difference of
the melting temperatures of the different genotypes, containing either
the original nucleotide sequence or the SNP. PCR mixture of the assays
composed of 2 μl 5X Colour-less GoTaq Flexi Buffer (Promega Inc.,
Madison, WI), 1.5 μl MgCl2 (25 mM), 0.3 μl dNTP (10 mM, Qiagen Inc.,
Valencia, CA), 0.5 μl EvaGreen (20X, Biotium Inc., Hayward, CA),
primers (10 pmol/μl, Table 1), 0.08 μl GoTaq G2 Flexi DNA polymerase
(5 U/μl; Promega Inc.) and 1 μl DNA template with a final volume of 10
μl. Thermocycling parameters were the following for the MAMAs, 95 °C
for 10 min, followed by 30 cycles (gyrA 242; 260, 23S rRNA) or 34
cycles (parC 239;250, gyrA 247) of 95 °C for 15 s and 45 s of 60 °C
(gyrA247), or 60 s of 55 °C (parC239;250)/ 56 °C (gyrA242;260)/ 60 °C
(23S rRNA). The PCR products were subjected to melt analysis using a
dissociation protocol comprising the steps 95 °C for 15 s, followed by
incremental temperature ramping of 0.3 °C from 60 °C to 95 °C. Eva-
Green fluorescence intensity was measured at 525 nm at each ramp
interval and plotted against temperature. The nucleotide sequences of
the primers and the utilised primer ratios are summarised in Table 1.
Melt-MAMAs were carried out on an Applied Biosystems Step-One Plus
real-time PCR system with StepOne Software™ v2.2.2.
Beside individual SNPs, a “hot-spot” region with two possible mu-
tations in the parC gene was identified in strains with declined fluor-
oquinolone susceptibility (Le Carrou et al., 2006). This region of the
parC gene (containing the nucleotide positions 239 and 250) was tar-
geted by HRM assay (Palais et al., 2005; Sulyok et al., 2018). The pri-
mers used during an HRM assay are summarised in Table 1. PCR mix-
ture of the assays composed of 2 μl 5X Colour-less GoTaq Flexi Buffer
(Promega Inc., Madison, WI), 1.5 μl MgCl2 (25 mM), 0.3 μl dNTP (10
mM, Qiagen Inc., Valencia, CA), 0.5 μl EvaGreen (20X, Biotium Inc.,
Hayward, CA), primers (10 pmol/μl, Table 1), 0.08 μl GoTaq G2 Flexi
Table 1
Characteristics of the primers and products used in the developed MAMA and HRM assays.
Assay type Antibiotic
group
Primer name with
target gene and SNPa
Primer sequence
(5’-3’)
Primerb (μl) Ta
(°C)
Type Tm
(°C)
Amplicon
(bp)
MAMA Fluoroquinolones gyrA_242C TTGAGCCATTCGCACCA 0.15 56 S
R
77.5-79.2
82.9-83.1
58
73gyrA_242S GAAAATACCATCCTCACGG 0.15
gyrA_242R ggggcggggcggggcGAAAATACCATCCTCAAGC 0.6
gyrA_247C TCCGCTAGAATTGTTGGTGA 0.15 60 S
R
77.1-78.1
81.0-81.7
73
88gyrA_247S ACCATCGATTCATAGACAGCAG 0.3
gyrA_247R ggggcggggcggggcACCATCGATTCATAGACAGCAA 0.15
gyrA_260C TTGTTGGTGATGTTCTTGG 0.15 56 S
R
77.9-79.2
82.6-82.8
70
85gyrA_260S CATTCGCACCATCGCTT 0.6
gyrA_260R ggggcggggcggggcCATTCGCACCATCGTTC 0.15
parC_239C AATCTGCTAGAGTTGTCGGTG 0.15 55 S
R
75.0-75.5
79.8-80.1
74
86parC_239S CAAGAGCATC/TATAGATTGgAG 0.15
parC_239R ggggcggggcggggcCAAGAGCATC/TATAGATTGcAA/T 0.15
parC_250C AATCTGCTAGAGTTGTCGGTG 0.15 55 S
R
77.0-77.9
80.7-81.1
84
96parC_250S GCAAGTCTGACAAGAGCgTC 0.15
parC_250R ggggcggggcggggcGCAAGTCTGACAAGAGCcTt 0.15
Macrolides,
Lincosamides
23S_2059C CCACCTATCCTACACATAATAAACC 0.15 60 S
R
76.9-77.2
79.0
85
9723S_2059S GTTA/TCCCGCATCAAGACaAA 0.15
23S_2059R ggggcggggcggggcGTTA/TCCCGCATCAAGACtAg 0.6
HRM Fluoroquinolones parC_239-250_R CATTCCTGGGCAAGTCTG 0.25 55 S
R
78.6-78.7
78.1-78.5
93
parC_239-250_F AATCTGCTAGAGTTGTCGGTG 0.25
Nucleotide sequences, annealing temperatures and ratios of the primers used for the assays and results including melting temperatures, sizes of the amplicons.
Artificial GC-tail of the primers, enabling the differentiation of the resistant genotypes are presented with lowercased letters.
Abbreviations: S-sensitive; R-resistant; C-consensus; Ta-annealing temperature; Tm-melting temperature.
a-nucleotide position according to E. coli numbering; b-primer amounts per sample in melt-MAMAs and HRM.
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DNA polymerase (5 U/μl; Promega Inc.) and 1 μl DNA template with a
final volume of 10 μl. Thermocycling parameters were the following for
the HRM assay, 95 °C for 10 min followed 34 cycles of 95 °C for 15 s and
55 °C for 60 s. The PCR products were subjected to melt analysis, with
an incremental temperature ramping of 0.1 °C from 60 °C to 95 °C. HRM
profiles were analysed using High Resolution Melt software, version
3.0.1 (Thermo Fisher Scientific Inc.). Fluorescent values were normal-
ised according to user-adjustable pre- and post-melting temperature
intervals.
2.3. Validation of the assays
In order to test the sensitivity of the MAMA and HRM assays, tenfold
dilutions of the type strain and strains showing increased MIC values
(MycSu1, 15, 18, 20, 39, and MycSu50) were used in the range of 106-
101 copy number/μl. The template copy number was calculated with
the help of an online tool (Staroscik, 2004) based on the length of the
whole genome sequence and concentration of DNA of pure M. hyop-
neumoniae cultures measured by Nanodrop 2000 Spectrophotometer
(Thermo Fisher Scientific Inc.). The lowest DNA concentrations (tem-
plate copy number) yielding melting temperature (Tm) specific to the
genotype were considered the detection limits of the assays. The spe-
cificity of the assays was tested by including pathogen and non-pa-
thogen porcine Mycoplasma species in the analysis: M. hyorhinis, M.
hyosynoviae and M. flocculare. The developed assays were tested on M.
hyopneumoniae isolates with previously accomplished microbroth dilu-
tion method also. Genotypes identified by the MAMA and HRM assays
were compared with MIC values of the 38 M. hyopneumoniae isolates.
3. Results
All of the developed MAMA and HRM assays successfully differ-
entiated the antibiotic sensitive and resistant genotypes (Fig. 1), and
correlated with the results of the previously accomplished microbroth
dilution method. Melting temperatures and cycle threshold (ct) values
of the assays are presented in Supplementary Table 1.
Five melt-MAMAs (targeting SNPs in the gyrA and parC genes) and
an HRM assay (targeting “hot-spot” region in the parC gene (Fig. 2)
were developed for the rapid detection of decreased fluoroquinolone
susceptibility of M. hyopneumoniae isolates and one melt-MAMA (tar-
geting SNP in the 23S rRNA region) was established for the detection of
macrolide and lincosamide susceptibility. Since the gyrA gene contained
several silent mutations beside the mentioned sense mutations, this
region was not suitable for the development of an HRM assay.
The sensitivity of the assays was 103 copy numbers/reaction for
both the sensitive and resistant genotypes in case of MAMAs targeting
the nucleotide substitution C247 T in the gyrA and G250A in the parC
gene. However, the sensitivity of the MAMAs targeting the alterations
A260 G in the gyrA gene and C239 T/A in the parC gene was 103 copies/
reaction for the sensitive genotype and 104 for the resistant genotype.
Furthermore, the sensitivity was 103 copies/reaction for the resistant
genotype and 104 for the sensitive genotype in case of MAMA targeting
the nucleotide change G242C in the gyrA gene. The sensitivity of the
MAMA differentiating sensitive and resistant genotypes according to
the nucleotide alteration A2059 G in the 23S rRNA sequence was 103
copies/reaction for both genotypes. Normalization interval of
74.0–74.5 °C and 81.0–81.5 °C were used in the HRM analysis of the
amplicons. The sensitivity of the HRM assay was 105 copies/reaction
for the sensitive genotype and for most types of the resistant genotype
(C239A or G250A), while the sensitivity of the system was 106 copies
per reaction in case of C239 T alteration of the parC gene (resistant
genotype). Melting temperature ranges and amplicon sizes are sum-
marised in Table 1. Cross-reactions were only observed using the
MAMAs targeting the nucleotide substitutions G250A in the parC gene
(M. flocculare) and A2059 G in the 23S rRNA sequence (M. flocculare,M.
hyorhinis), none of the other assays showed false positivity.
4. Discussion
Since vaccination does not provide complete protection against M.
hyopneumoniae infection (Meyns et al., 2004, 2006; Stakenborg et al.,
2006; Villarreal et al., 2009), targeted antimicrobial therapy plays an
important role in the control of enzootic pneumonia in the pig industry.
Antimicrobials are able to reduce clinical symptoms, moderate the
mortality rate and increase weight-gain of the animals (Maes et al.,
1996; Pallarés et al., 2015). However, conventional antibiotic sus-
ceptibility testing is usually not accomplished before the therapy, be-
cause it is extremely time-consuming, could take even up to months
(Hannan, 2000). Therefore, the choice of the antimicrobial is usually
based on earlier experiences.
In the present study, six MAMAs and one HRM assay were suc-
cessfully designed for the fast detection of SNPs correlating with
fluoroquinolone, macrolide and lincosamide resistance in M. hyopneu-
moniae. Although the mentioned agents are discouraged to be used in
veterinary praxis, these agents showed decreased effectiveness against
M. hyopneumoniae before (Gautier-Bouchardon, 2018; Felde et al.,
2018) and SNPs showing correlation with decreased antibiotic sus-
ceptibility of M. hyopneumoniae were described previously only in case
of the mentioned antibiotics (Gautier-Bouchardon, 2018). The results of
the MAMA and HRM assays were congruent with that of the conven-
tional microbroth dilution test. MAMA systems are cost-effective and
widely available methods for diagnostic purposes. The developed HRM
assay serves as confirmation option in well-equipped laboratories. Both
MAMA and HRM are standard methods providing results in con-
siderably shorter time (hours after isolation) compared to the conven-
tional antibiotic susceptibility tests (requiring months to perform and
special conditions which still need to be standardized).Furthermore,
these MAMA and HRM systems can serve as examples for further assay
developments. Since HRM assays are designed to examine “hot spot”
regions, containing closely localised SNPs within a sequence; and only
one SNP showed correlation with decreased macrolide and lincosamide
susceptibility of the Hungarian isolates, therefore no HRM test was
developed for the investigation of the mentioned antibiotics.
According to the number of the observed amino acid alterations,
two subgroups of the fluoroquinolone resistant genotype were defined.
The presence of SNP in the parC gene correlated with moderately in-
creased MIC values of fluoroquinolones, while the increase of MIC va-
lues was more pronounced in case of double substitutions in the parC
and gyrA genes. Since both the single and double substitutions show
correlation with increased MIC values, the use of all five MAMAs is
suggested for the exclusion of decreased fluoroquinolone susceptibility.
The target positions in the parC gene can be investigated either by HRM
assay (detecting both C239A/T and G250A substitutions in a single
investigation; although it requires special laboratory equipment), or by
the two melt-MAMAs using the same temperature profile. Furthermore,
two of the three nucleotide substitutions in the gyrA gene can be de-
tected simultaneously, thus application of the developed assays can
provide results within 10–12 hours. According to their sensitivity, the
assays are suggested to be utilised forM. hyopneumoniae isolates instead
of clinical material, therefore the observed cross-reactions can be ig-
nored.
Although certain mutations in the target regions of the antibiotics
seem to correlate with increased in vitro MIC values (Stakenborg et al.,
2005; Le Carrou et al., 2006; Vicca et al., 2007; Gautier-Bouchardon,
2018), PCR-based susceptibility testing of M. hyopneumoniae has not
been published before. Due to the limited number of publications and
sequence data of M. hyopneumoniae strains showing decreased anti-
biotic susceptibility, the development of the MAMA and HRM assays is
also limited and challenging. The MAMA and HRM assays described in
the present study offer reliable guidance for antibiotic therapy against
M. hyopneumoniae. The application of the developed assays for the
determination of antibiotic susceptibility of circulating M. hyopneumo-
niae strains would improve the targeted treatment of enzootic
O. Felde, et al. Veterinary Microbiology 245 (2020) 108697
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pneumonia.
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Fig. 1. Mismatch amplification mutation assay targeting the nucleotide substitution G242C in the gyrA gene of fluoroquinolone sensitive and resistantM.
hyopneumoniae strains.
Fluoroquinolone sensitive type (blue lines) (Tm = 78.1–78.4 °C), fluoroquinolone resistant type (green lines) (Tm = 82.9–83.1 °C) and negative control (grey line)
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online version, at doi:https://doi.org/10.1016/j.vetmic.2020.108697.
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